Webster Financial (NYSE: WBS) has opened the week down after missing first quarter estimates on both EPS and revenue. The Waterbury, Connecticut-based firm's EPS grew nearly five percent to $0.44, but rounded out shy of the $0.46 analysts hoped for. Revenue finished up 1.7 percent year-over-...

In a report published Wednesday, Zacks reiterated its Outperform rating and $9.50 price target on POZEN (NASDAQ: POZN). Zacks noted, “The phase 3 clinical data on Pozen s PA-325/40 product has been presented now at three high-profile medical meetings, ACG in October 2012, AHA in November 2012, and...

Zacks downgraded Pure Bioscience (NASDAQ: PURE) from Outperform to Neutral with a $1.75 price target. Zacks said, "[W]e are concerned about the slow sales ramp for the Company s SDC products. Although its lead product PURE Hard Surface is increasingly gaining recognition, sales may take longer...

Coffee distributors far and wide are praying for Starbucks (NASDAQ: SBUX) to hit some type of snafu, as the coffee giant has noticeably dominated the market in recent weeks, forcing analysts to raise its rating/estimates and lower those of the competition. Within the last month, Starbucks stock...

Zacks reiterates its Outperform rating and $8.50 price target on Clean Diesel Tech (NASDAQ: CDTI) as the company expects a big fourth quarter. Zacks says, "Clean Diesel Technologies announced that the fourth quarter is expected to be largest revenue quarter in 2011. In the third quarter it...

Power-One (NASDAQ: PWER) shares are down ~4% since market open and has been called one of today's worst performing stocks by Financial News Network Online, which also points out that Power-One has traded 1 million shares today vs. its average volume of 3.4 million. So what gives? On October 28...

Zacks is out with its report today on FutureFuel (NYSE: FF), initiating FF at Outperform. In its report, Zacks writes, "FutureFuel is a profitable manufacturer and seller of specialty chemicals. We are initiating coverage with an Outperform rating and a price target of $16.00." Shares of FF...

Zacks is out with its report today on EpiCept (NASDAQ: EPCT), maintaining Outperform. In its report, Zacks writes, "The Company s lead cancer candidate Ceplene has been already approved in EU and Israel for the remission maintenance of AML and a pivotal trial is planned in the US. The Company s...

Zacks is out with its report today on S&W Seed (NASDAQ: SANW), maintaining Outperform. In its report, Zacks writes, "S&W Seed is a profitable developer of drought and salt resistant alfalfa seed varieties. The company has unused processing capacity that, when utilized, provides significant...

Zacks initiated its coverage of iCAD (NASDAQ: ICAD) with Neutral. On Tuesday, ICAD closed the day at $1.